SCHEMBL4504292

SCHEMBL4504292

COc1ccccc1C(C(N)=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.51
TDO2 P48775 1/20 0.51
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
POLB P06746 2/20 0.47
HTT P42858 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
GFER P55789 1/20 0.46
HPGD P15428 1/20 0.45
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9336726 0.86 KMT2A (0.53) IDO1TDO2KMT2AMEN1CRHBP
SCHEMBL6183696 0.85 ADRA1A (0.50) KMT2AMEN1HTTNPSR1SMN1; SMN2
SCHEMBL4503545 0.84 LMNA (0.43) KMT2AMEN1CRHBPCRHR2POLB
SCHEMBL27486101 0.83 KMT2A (0.55) IDO1TDO2KMT2AMEN1CRHBP
SCHEMBL4504332 0.82 KDM4E (0.43) KMT2AMEN1HTTL3MBTL1SMN1; SMN2
SCHEMBL4509859 0.82 LMNA (0.42) KMT2AMEN1HTTL3MBTL1SMN1; SMN2
SCHEMBL16781989 0.81 L3MBTL1 (0.61) IDO1TDO2KMT2AMEN1CRHBP
SCHEMBL306964 0.80 CA1 (0.54) IDO1TDO2KMT2APOLBHTT
SCHEMBL29386813 0.80 CA1 (0.54) IDO1TDO2KMT2APOLBHTT
SCHEMBL27456672 0.79 MEN1 (0.50) IDO1TDO2KMT2AMEN1CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed
CN-1553900-A Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents ��ʱ��ʩ����ҩ��˾ 2004-12-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 IDO1 1672/4885TDO2 1663/4885KMT2A 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.